Previous 10 | Next 10 |
2024-05-22 13:32:00 ET Summary Australia to ban compounded versions of Novo Nordisk's semaglutide and Eli Lilly's tirzepatide due to safety concerns. Existing home sales dipped 1.89% in April to 4.14 million. All eyes on Nvidia earnings but BofA points to another stock that de...
2024-05-22 11:25:25 ET More on Novo Nordisk The FTC Cracks Down On Novo Nordisk's Ozempic Novo Nordisk A/S 2024 Q1 - Results - Earnings Call Presentation Novo Nordisk A/S (NVO) Q1 2024 Earnings Call Transcript Novo Nordisk office building fire brought under c...
2024-05-22 10:01:06 ET More on NeuroBo Pharmaceuticals NeuroBo Phase 2a study for MASH drug to proceed as planned NeuroBo stock jumps 14% on weight-loss drug update Seeking Alpha’s Quant Rating on NeuroBo Pharmaceuticals Historical earnings data for Ne...
2024-05-22 08:13:08 ET More on Novo Nordisk The FTC Cracks Down On Novo Nordisk's Ozempic Novo Nordisk A/S 2024 Q1 - Results - Earnings Call Presentation Novo Nordisk A/S (NVO) Q1 2024 Earnings Call Transcript Australia to ban copycat versions of weight loss ...
2024-05-22 07:51:38 ET More on Hims & Hers Health Hims & Hers: Soaring On Access To Compounded GLP-1 Drugs, Further Volatility Ahead 10 Solid Reasons To Buy Hims & Hers Stock Hims & Hers: Strong Operating Leverage And Profitability Inflection ...
2024-05-22 07:14:37 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly: Great Time To Divest Before It Potentially Crashes Eli Lilly Remains Expensive Here - Minimal Margin Of Safety The FTC Cracks Down On Novo Nordisk's Ozempic Study finds 30% of Wegovy, Sax...
2024-05-21 14:06:23 ET More on Novo Nordisk The FTC Cracks Down On Novo Nordisk's Ozempic Novo Nordisk A/S 2024 Q1 - Results - Earnings Call Presentation Novo Nordisk A/S (NVO) Q1 2024 Earnings Call Transcript Novo Nordisk unsure when it will meet obesity dru...
2024-05-21 11:50:45 ET More on Novo Nordisk The FTC Cracks Down On Novo Nordisk's Ozempic Novo Nordisk A/S 2024 Q1 - Results - Earnings Call Presentation Novo Nordisk A/S (NVO) Q1 2024 Earnings Call Transcript Microcap Mangoceuticals doubles on plan to sell c...
2024-05-21 10:29:09 ET More on Weight Loss Drugs Hims & Hers: Soaring On Access To Compounded GLP-1 Drugs, Further Volatility Ahead Genetics may determine who responds well to Wegovy: report One in eight U.S. adults admits to GLP-1 usage as public aware...
2024-05-21 09:21:57 ET More on Eli Lilly, Novo Nordisk Eli Lilly: Great Time To Divest Before It Potentially Crashes Eli Lilly Remains Expensive Here - Minimal Margin Of Safety The FTC Cracks Down On Novo Nordisk's Ozempic Eli Lilly inks radiopharma deal wort...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...
2024-07-17 13:21:54 ET Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that no...
2024-07-14 05:20:00 ET Two pharma juggernauts, Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) , are picking up speed in their preparations for an epic battle to control the market for weight loss drugs. The prize for the victor will be a larger market share of what may b...